What is PLSE's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 3.23B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PLSE?

P/E (TTM) is n/a and 52-week range is $12.56 to $58.90 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PLSE figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PLSE?

The company profile lists revenue (TTM) near $1M, net income (TTM) near $-8.00B, EPS (TTM) near $-1.17 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Pulse Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Hayward, California, US, 69.2M shares outstanding, ISIN US74587B1017 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Pulse Biosciences Inc (PLSE) Stock Analysis & Quote

Free AI scores & summaries library

Pulse Biosciences Inc

$PLSE

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$44.43

-2.54%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. The company is headquartered in Hayward, California and currently employs 116 full-time employees. The company went IPO on 2016-05-18. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The company is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.

Employees

116

Website

www.pulsebiosciences.com/

IPO

2016-05-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)